A team at Aria Neurosciences of Hamden has published preclinical results for its compound ARN-2966 (2-PMAP). Research revealed that 2-PMAP reduced the production of amyloid beta’s mother protein, known as amyloid precursor protein, and also had the same impact on amyloid proteins in the brains of transgenic mice used as animal models of Alzheimer’s disease. Importantly 2-PMAP also prevented the cognitive deficits that are normally seen in these mice as they age.